Sector News

China pledges US$ 100 million towards equitable access to COVID-19 vaccines for lower-income countries

August 22, 2021
Life sciences

The Government of the People’s Republic of China (China) has pledged US$ 100 million to the Gavi COVAX Advance Market Commitment (Gavi COVAX AMC). The announcement, made at the International Forum on COVID-19 Vaccine Cooperation, hosted by China, is the country’s largest voluntary pledge to an international organisation to-date.

This latest donor pledge brings the total amount raised for the Gavi COVAX AMC, the mechanism which enables supply of donor-funded vaccines to 92 low- and middle-income countries, to nearly US$ 10 billion – further reaffirming the role of COVAX as the only global, multilateral response focused on equitable access to COVID-19 vaccines regardless of income level.

“We welcome this contribution from China, which will enable further access to COVID-19 vaccines for the most at risk in low- and middle-income countries,” said Dr Seth Berkley, CEO of Gavi, the Vaccine Alliance, which leads on procurement and delivery at scale for COVAX and manages the COVAX Facility as well as the Gavi COVAX AMC. “In a time of vaccine inequity combined with the rising threat of variants, it is more important than ever for countries and manufacturers to come together to support COVAX in delivering on its vision of global equitable access.”

China first became a donor to Gavi in 2015, with US$ 25 million pledged in total to-date towards Gavi’s core work on routine immunisation.

“China will continue to do its best to help other lower income countries cope with the COVID-19 pandemic”, said President Xi Jinping of China, “and we stand ready to work with international organizations to advance vaccine cooperation to protect communities for a shared future.”

COVAX has delivered more than 188 million doses to 138 countries to date – the majority to lower-income countries supported by the Gavi COVAX AMC – with delivery of supplies secured both via COVAX Facility deals as well as dose donations picking up pace over the last few weeks.

COVAX anticipates supplying its participants with more than 2 billion doses by early 2022, including at least 1.8 billion donor-funded doses to be made available to AMC participants.

By GAVI, Press Release

Source: gavi.org

comments closed

Related News

June 16, 2024

Bayer’s biotech head Jens Vogel says good-bye after 4 years

Life sciences

While Vogel didn’t cite any broader organizational changes as the reason behind his resignation, his departure comes amid a heavy-handed restructuring at the German pharma. Back in January, Bayer unveiled plans that have ultimately led to the elimination of more than 1,500 roles in the first three months of 2024.

June 16, 2024

Ventilator maker Vyaire Medical files for bankruptcy

Life sciences

The global ventilation and respiratory device manufacturer—originally spun out as a joint venture between BD and Apax Partners in 2016—said its decision followed “below-plan performance in the first half of the financial year, which frustrated efforts to refinance company debt,” and that Vyaire will remain open for business in the interim.

June 16, 2024

Pfizer, Flagship name first target for multibillion-dollar collaboration: obesity

Life sciences

Pfizer and Flagship Pioneering have settled on the first target for their billion-dollar, multiprogram collaboration, and it’s not exactly a surprise: The New York Big Pharma giant will work with the venture creation firm’s ProFound Therapeutics to develop new obesity drugs.

How can we help you?

We're easy to reach